Nature Reviews Drug Discovery

A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails. Find out more in this news story in the July issue nature.com/articles/d4157…

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development rdcu.be/ftz8C nature.com/articles/s4157… This new Perspective discusses the value of trial simulations, presents best-practice recommendations and describes case studies of impact

mRNA technology is one of the platforms being used for n-of-1 therapies. Read about its application in this and a range of other areas such as in vivo CAR-T cell therapies and cancer immunotherapies in this Review nature.com/articles/s4157… rdcu.be/fteeb

For readers interested in the development of n-of-1 therapies, such as custom gene editing drugs, here's a roadmap from @irdirc nature.com/articles/s4157… rdcu.be/ftec1

ARPA-H invests $160 million to make custom gene editing routine | STAT statnews.com/2026/07/09/arp…

For readers interested in therapeutic strategies for chronic obstructive pulmonary disease (COPD), such as PDE3/4 inhibition - the focus of AstraZeneca's latest potential $2.1 billion deal - here's a review nature.com/articles/s4157… rdcu.be/fs1jW

AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre fiercebiotech.com/biotech/astraz…

For readers interested in claudins as therapeutic targets in cancer, including claudin 18.2 - the target of the first CAR-T cell therapy to be approved for a solid tumour - here's a comprehensive recent review nature.com/articles/s4157… rdcu.be/fp0UQ

CAR T cell therapy for solid cancer scores first approval in China nature.com/articles/d4157… CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma

For readers interested in therapeutic epigenetic editing, which aims to reprogramme gene expression by rewriting epigenetic signatures without editing of the genome, here's a comprehensive review nature.com/articles/s4157… rdcu.be/fsCoc

Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials fiercebiotech.com/biotech/scribe…

Small-molecule drug candidates increasingly have limited aqueous solubility, making oral delivery challenging. This article in the July issue discusses formulation approaches to mitigate solubility and dissolution rate limitations nature.com/articles/s4157… rdcu.be/fsjUt

Our July issue is live! Read about multispecific biologics, AI in target identification and assessment, CDK inhibitors as cancer therapies, the role of formulations in oral delivery of poorly water-soluble drugs and more here nature.com/nrd/volumes/25…

R&D productivity trends for biopharma companies in Asia and emerging markets nature.com/articles/d4157… This article analyses data from 2010-2025 for 45 biopharma companies based in Asia, Latin America and EEMEA to evaluate R&D productivity trends and develop a strategic framework

Growth in clinical research capability in China and impact on the pharmaceutical sector nature.com/articles/d4157… This new article analyses data on the growth in inputs to clinical research capability in China and its impact on outputs such as investigator-initiated trials

For readers interested in mRNA therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies, here's a comprehensive review nature.com/articles/s4157… rdcu.be/friiI

In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for biotech. trib.al/o1eTzLQ

The history and future of cancer immunotherapy is being discussed at a panel at #BIO2026 , and agonistic antbody immunotherapies have been highlighted - here's a comprehensive review on realizing their potential nature.com/articles/s4157… rdcu.be/fqohC

Time to peak sales: how long is the climb? nature.com/articles/d4157… This new article analyses trends in the time to peak sales for drugs launched in the past two decades and the underlying drivers

Multispecific T-cell engagers attract cancer drug developers nature.com/articles/d4157… Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors